Metastatic Triple-Negative Breast Cancer

This article is a review of the latest key literature in the management of metastatic TNBC and offers a glimpse of ongoing drug development.Recent FindingsRecent paradigm-shifting trials led to the incorporation of immune checkpoint inhibitors with chemotherapy in the frontline setting for TNBC with positive PDL1-expression. Novel antibody –drug conjugates with new targets (Trop2, HER2) now offer additional treatment options for metastatic TNBC.SummaryThere have been significant strides in understanding the tumor-immune microenvironment and molecular vulnerabilities in TNBC. As the treatment of metastatic TNBC evolves rapidly, novel combination therapies and therapeutic strategies will continue to improve patient outcomes.

http://link.springer.com/10.1007/s12609-023-00493-3

Source: Current Breast Cancer Reports - June 17, 2023 Category: Cancer & Oncology Source Type: research